RSV Vaccine with Nanoparticle-Based Poly-Sorbitol Transporter (PST) Adjuvant Improves Respiratory Protection Against RSV Through Inducing Both Systemic and Mucosal Humoral Immunity

<b>Background/Objectives:</b> Respiratory syncytial virus (RSV) causes symptoms similar to a mild cold for adults, but in case of infants, it causes bronchitis and/or pneumonia, and in some cases, mortality. Mucosal immunity within the respiratory tract includes tissue-resident memory T (T<sub>RM</sub>) cells and tissue-resident memory B (B<sub>RM</sub>) cells, which provides rapid and efficient protection against RSV re-infection. Therefore, vaccine strategies should aim to generate mucosal immune responses. However, the interactions between RSV vaccines and mucosal immune responses within the respiratory tract are poorly understood. We evaluated a mucosal immune system following immunization by RSV vaccine with poly-sorbitol transporter (RSV-PST), a nanoparticle adjuvant. <b>Methods:</b> We intranasally immunized the RSV-PST and identified the systemic and mucosal immune responses. Furthermore, we challenged with RSV A2 strain after immunization and investigated the protective effects. <b>Results:</b> Consequently, antigen-specific CD8<sup>+</sup> T<sub>RM</sub> cells were markedly elevated in the lung parenchyma, yet exhibited impaired cytokine expression. In contrast, humoral immunity, with systemic antibody production from serum, but not in the respiratory tract, was significantly increased by RSV-PST immunization. Interestingly, the production of respiratory mucosal antigen-specific IgG after RSV A2 challenge dramatically increased in the bronchoalveolar lavage fluid (BALF) of the RSV-PST immunized group in the presence of FTY720, and the lung-infected RSV titer was significantly lower in this group. Furthermore, after RSV A2 challenge, CD69<sup>+</sup> IgG<sup>+</sup> B<sub>RM</sub> cells were significantly increased in lung tissues in the RSV-PST group. <b>Conclusions:</b> The RSV-PST vaccine has protective effects against RSV infection by promoting both systemic and local humoral immunity rather than cellular immunity.

Authors

Institutions

Publication Details

Journal
Vaccines
Published
2024-11-29
DOI
https://doi.org/10.3390/vaccines12121354
Citations
1
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
0.39

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

RSV Vaccine with Nanoparticle-Based Poly-Sorbitol Transporter (PST) Adjuvant Improves Respiratory Protection Against RSV Through Inducing Both Systemic and Mucosal Humoral Immunity

Cheol Gyun Kim, Taewoo Kim, In Su Cheon, Young Min Son et al.
1 citations
Vaccines
Respiratory viral infections research
0.39
article

RSV Vaccine with Nanoparticle-Based Poly-Sorbitol Transporter (PST) Adjuvant Improves Respiratory Protection Against RSV Through Inducing Both Systemic and Mucosal Humoral Immunity

Cheol Gyun Kim, Taewoo Kim, In Su Cheon, Young Min Son, Jun Chang, Soo Ji Kim, Eun Suk Seo, Sumin Lee, Cheol‐Heui Yun, Eunjin Cho, Young Chae Park, Byoung-Shik Shim, Seong-Mook Jung
article en
1 citations

Abstract

<b>Background/Objectives:</b> Respiratory syncytial virus (RSV) causes symptoms similar to a mild cold for adults, but in case of infants, it causes bronchitis and/or pneumonia, and in some cases, mortality. Mucosal immunity within the respiratory tract includes tissue-resident memory T (T<sub>RM</sub>) cells and tissue-resident memory B (B<sub>RM</sub>) cells, which provides rapid and efficient protection against RSV re-infection. Therefore, vaccine strategies should aim to generate mucosal immune responses. However, the interactions between RSV vaccines and mucosal immune responses within the respiratory tract are poorly understood. We evaluated a mucosal immune system following immunization by RSV vaccine with poly-sorbitol transporter (RSV-PST), a nanoparticle adjuvant. <b>Methods:</b> We intranasally immunized the RSV-PST and identified the systemic and mucosal immune responses. Furthermore, we challenged with RSV A2 strain after immunization and investigated the protective effects. <b>Results:</b> Consequently, antigen-specific CD8<sup>+</sup> T<sub>RM</sub> cells were markedly elevated in the lung parenchyma, yet exhibited impaired cytokine expression. In contrast, humoral immunity, with systemic antibody production from serum, but not in the respiratory tract, was significantly increased by RSV-PST immunization. Interestingly, the production of respiratory mucosal antigen-specific IgG after RSV A2 challenge dramatically increased in the bronchoalveolar lavage fluid (BALF) of the RSV-PST immunized group in the presence of FTY720, and the lung-infected RSV titer was significantly lower in this group. Furthermore, after RSV A2 challenge, CD69<sup>+</sup> IgG<sup>+</sup> B<sub>RM</sub> cells were significantly increased in lung tissues in the RSV-PST group. <b>Conclusions:</b> The RSV-PST vaccine has protective effects against RSV infection by promoting both systemic and local humoral immunity rather than cellular immunity.

VaccinesVol. 12(12)
International Vaccine Institute (KR), Mayo Clinic (US), Ewha Womans University (KR), Seoul National University (KR), Chung-Ang University (KR)
National Research Foundation, Korea Health Industry Development Institute, National Research Foundation of Korea, Ministry of Science and ICT, South Korea
Good health and well-being
Openalex Percentile: Top 32%
Respiratory viral infections research
0.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.